Oppenheimer Maintains Outperform on Viking Therapeutics, Raises Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Viking Therapeutics (NASDAQ:VKTX) and increased the price target from $116 to $138.
March 26, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Viking Therapeutics and raised the price target from $116 to $138.
The increase in price target by a reputable analyst suggests a strong bullish outlook on Viking Therapeutics, likely leading to positive investor sentiment and potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100